The companies plan to combine their expertise in artificial intelligence and genomic data analyses to develop new precision medicine tools.
Two years in, the MUSC Program for Human Microbiome Research is finding its footing, but it has high ambitions for creating safer care environments.
"Precision metagenomics" and "geospatially informed medical care" are among the long-term goals of the $5 million WorldQuant Initiative for Quantitative Prediction at Weill Cornell Medicine.
Called CanPathPro, the research consortium aims to combine omics data and systems biology tools into a single commercial platform for testing cancer hypotheses.
Snyder's new book, "Genomics and Personalized Medicine," serves as a primer for patients and doctors, touching on topics from tailored cancer therapy to wearable devices.
Though cancer experts noted many tests under MEDCAC review were developed to be predictive of treatment response, CMS maintained the meeting's focus on the prognostic context.
The HIV Treatment Response Prediction System averages the output of four trained random forest models to predict response to antiretroviral drugs based on viral load, CD4 counts, HIV genotypes, and records of antiretroviral drug treatments.
The patents add to others held by Myriad covering pancreatic cancer markers.
Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.
A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.
In Science this week: CRISPR-based approach for recording cellular events, and more.
A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.